Page 16 - நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stem cell therapy company Amniotics raises SEK 60 million before deduction of transaction costs, in First North IPO to advance lead candidate PulmoStem™ into clinic USA - English News provided by Share this article LUND, Sweden, July 12, 2021 /PRNewswire/ Amniotics AB (publ) ( Amniotics or the Company ), a stem cell therapy company has raised SEK60 million through its recent listing on Nasdaq First North Growth Market. The offering was fully subscribed and attracted widespread interest from Swedish investment companies and family offices as well as the general public in Sweden, Norway and Finland. The funds will now be deployed to advance the company s preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic in Q2, 2022. In addition, Amniotics will expand its stem cell GMP manufacturing services to research and i

Northern ostrobothniaLund university stem cell centreUniversity hospital of lundNasdaq first north growthUniversity hospitalGood manufacturing practiceAdvanced therapy medicinalNasdaq first north growth marketJohny humalojaவடக்கு ஒஸ்திரோபோடஞியநாஸ்டாக் முதல் வடக்கு வளர்ச்சிபல்கலைக்கழகம் மருத்துவமனைநல்ல உற்பத்தி ப்ர்யாக்டீஸ்நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை